Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.20
-16.5%
$0.24
$0.17
$3.93
$639K-0.09130,418 shs305 shs
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
$0.60
$0.59
$0.59
$0.60
$31.81M-0.151 shsN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.30
-3.3%
$0.81
$0.25
$4.71
$4.41M1.571.89 million shs2.44 million shs
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$1.26
$1.07
$3.40
$30.33M0.2171,840 shs676,700 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.39
+6.6%
$0.34
$0.22
$4.19
$15.25M-0.433.12 million shs1.22 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-16.51%-16.41%-7.89%-30.79%-94.27%
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00%0.00%0.00%+31.90%+335.73%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-3.30%+10.22%-66.33%-68.52%-91.42%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
0.00%0.00%0.00%0.00%-23.53%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+6.62%+16.77%+3.27%-3.14%-90.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
2.524 of 5 stars
0.04.00.04.62.20.01.9
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.2807 of 5 stars
3.52.00.00.04.01.71.3
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.0813 of 5 stars
0.05.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00
N/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.001,224.94% Upside
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
3.00
Buy$14.00∞ Upside
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MBRX, OCUP, ATXI, PRPH, and HBPCF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/9/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$4.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
$16.45M0.00N/AN/A$2.20 per share0.00
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$6.77M2.40N/AN/A$0.25 per share1.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M$18.350.01N/AN/A-471.57%-296.50%8/7/2025 (Estimated)
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
-$6.82M-$0.14N/AN/AN/AN/A-694.39%N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
-$9.99M-$0.49N/AN/AN/A-85.75%-30.19%-27.55%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$1.26N/AN/AN/A-217.64%-184.38%-64.59%8/13/2025 (Estimated)

Latest MBRX, OCUP, ATXI, PRPH, and HBPCF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/16/2025Q3 2025
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A-$0.02N/A-$0.02N/AN/A
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
5/13/2025Q1 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.71-$0.69+$0.02-$0.69N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
0.99
0.99
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.35
1.35
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
N/A
10.68
10.68
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.30
1.03
0.98

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
14.97%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
953.02 million48.99 millionNot Optionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2014.13 million13.86 millionNot Optionable
Ocuphire Pharma, Inc. stock logo
OCUP
Ocuphire Pharma
1425.92 million24.47 millionOptionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million37.55 millionOptionable

Recent News About These Companies

ProPhase Labs Q1 2025 Earnings Preview
ProPhase Labs's Earnings Outlook
ProPhase Labs Delays Form 10-Q Filing
ProPhase Labs reports FY24 EPS ($2.61) vs (98c) last year

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.20 -0.04 (-16.51%)
As of 06/30/2025 09:30 AM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Helix Biopharma stock logo

Helix Biopharma OTCMKTS:HBPCF

$0.60 0.00 (0.00%)
As of 06/27/2025

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.30 -0.01 (-3.30%)
As of 06/30/2025 04:00 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Ocuphire Pharma stock logo

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.39 +0.02 (+6.62%)
As of 06/30/2025 04:00 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.